{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:02:23Z","timestamp":1793275343479,"version":"4.5.0"},"reference-count":45,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"Importance<\/jats:title>Xerostomia is a major toxic effect associated with intensity-modulated radiotherapy (IMRT) for oropharyngeal cancers.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess whether adaptive radiotherapy (ART) improves salivary function compared with IMRT in patients with head and neck cancer.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This phase 3 randomized clinical trial was conducted in 11 French centers. Patients aged 18 to 75 years with stage III-IVB squamous cell oropharyngeal cancer treated with chemoradiotherapy were enrolled between July 5, 2013, and October 1, 2018. Data were analyzed from November 2021 to May 2022.<\/jats:p><\/jats:sec>Interventions<\/jats:title>The patients were randomly assigned (1:1) to receive standard IMRT (without replanning) or ART (systematic weekly replanning).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary end point was the frequency of xerostomia, measured by stimulating salivary flow with paraffin. Secondary end points included salivary gland excretory function measured using technetium-99m pertechnetate scintigraphy, patient-reported outcomes (Eisbruch xerostomia-specific questionnaire and the MD Anderson Symptom Inventory for Head and Neck Cancer questionnaire), early and late toxic effects, disease control, and overall and cancer-specific survival.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 132 patients were randomized, and after 1 exclusion in the ART arm, 131 were analyzed: 66 in the ART arm (mean [SD] age at inclusion, 60 [8] years; 57 [86.4%] male) and 65 in the standard IMRT arm (mean [SD] age at inclusion, 60 [8] years; 57 [87.7%] male). The median follow-up was 26.4 months (IQR, 1.2-31.3 months). The mean (SD) salivary flow (paraffin) at 12 months was 630 (450) mg\/min in the ART arm and 584 (464) mg\/min in the standard arm (P<\/jats:italic>\u2009=\u2009.64). The mean (SD) excretory function of the parotid gland at 12 months, measured by scintigraphy, improved in the ART arm (48% [17%]) compared with the standard arm (41% [17%]) (P<\/jats:italic>\u2009=\u2009.02). The 2-year-overall survival was 76.9% (95% CI, 64.7%-85.4%) in both arms.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This randomized clinical trial did not demonstrate a benefit of ART in decreasing xerostomia compared with standard IMRT. No significant differences were found in secondary end points except for parotid gland excretory function, as assessed by scintigraphy, or in survival rates.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT01874587<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2023.1352","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T15:32:29Z","timestamp":1685633549000},"page":"1056","source":"Crossref","is-referenced-by-count":76,"title":["Weekly Adaptive Radiotherapy vs Standard Intensity-Modulated Radiotherapy for Improving Salivary Function in Patients With Head and Neck Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Jo\u00ebl","family":"Castelli","sequence":"first","affiliation":[{"name":"University of Rennes, CLCC Eug\u00e8ne Marquis, Inserm, LTSI\u2013UMR 1099, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Thariat","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Centre Fran\u00e7ois Baclesse, Laboratoire de Physique Corpusculaire, Normandie Universite, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Benezery","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Centre Antoine Lacassagne, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hasbini","sequence":"additional","affiliation":[{"name":"Radiotherapy, Clinique Pasteur-Lanroze, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Gery","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Centre Fran\u00e7ois Baclesse, Laboratoire de Physique Corpusculaire, Normandie Universite, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Berger","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, CHU Poitiers, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Liem","sequence":"additional","affiliation":[{"name":"Academic Department of Radiation Oncology and Brachytherapy, Oscar Lambret Center, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Guihard","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Institut de Canc\u00e9rologie Strasbourg Europe, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Chapet","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, CHU Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Thureau","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Centre Henri Becquerel, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Auberdiac","sequence":"additional","affiliation":[{"name":"Radiotherapy, Clinique Claude Bernard, Albi, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Pommier","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Centre L\u00e9on B\u00e9rard, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Ruffier","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, CHU Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Perrier","sequence":"additional","affiliation":[{"name":"University Lyon, L\u00e9on B\u00e9rard Cancer Centre, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Devillers","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Centre Eug\u00e8ne Marquis, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Campillo-Gimenez","sequence":"additional","affiliation":[{"name":"University of Rennes, CLCC Eug\u00e8ne Marquis, Inserm, LTSI\u2013UMR 1099, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"de Crevoisier","sequence":"additional","affiliation":[{"name":"University of Rennes, CLCC Eug\u00e8ne Marquis, Inserm, LTSI\u2013UMR 1099, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9208","key":"coi230018r1","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(00)90011-4","article-title":"Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data.","volume":"355","author":"Pignon","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"coi230018r2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"issue":"6","key":"coi230018r3","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"issue":"10166","key":"coi230018r4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"issue":"31","key":"coi230018r5","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.1200\/JCO.2007.11.5501","article-title":"Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients.","volume":"25","author":"Kam","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi230018r6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1470-2045(10)70290-4","article-title":"Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.","volume":"12","author":"Nutting","year":"2011","journal-title":"Lancet Oncol"},{"issue":"4","key":"coi230018r7","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.ijrobp.2006.06.013","article-title":"Xerostomia and quality of life after intensity-modulated radiotherapy vs conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial.","volume":"66","author":"Pow","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"coi230018r8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/(ISSN)1097-0347","article-title":"Radiation-induced xerostomia.","volume":"29","author":"Chambers","year":"2007","journal-title":"Head Neck"},{"key":"coi230018r9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13014-014-0318-z","article-title":"Impact of head and neck cancer adaptive radiotherapy to spare the parotid glands and decrease the risk of xerostomia.","volume":"10","author":"Castelli","year":"2015","journal-title":"Radiat Oncol"},{"issue":"3","key":"coi230018r10","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ijrobp.2010.03.014","article-title":"Adaptive planning in intensity-modulated radiation therapy for head and neck cancers: single-institution experience and clinical implications.","volume":"80","author":"Ahn","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"coi230018r11","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ijrobp.2010.10.072","article-title":"A clinical concept for interfractional adaptive radiation therapy in the treatment of head and neck cancer.","volume":"82","author":"Jensen","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"coi230018r12","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1080\/0284186X.2018.1505053","article-title":"Adaptive radiotherapy for head and neck cancer.","volume":"57","author":"Castelli","year":"2018","journal-title":"Acta Oncol"},{"issue":"3","key":"coi230018r13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.clon.2011.11.005","article-title":"Adaptive radiotherapy using helical tomotherapy for head and neck cancer in definitive and postoperative settings: initial results.","volume":"24","author":"Capelle","year":"2012","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"3","key":"coi230018r14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00066-011-0041-8","article-title":"Adaptive radiotherapy for soft tissue changes during helical tomotherapy for head and neck cancer.","volume":"188","author":"Duma","year":"2012","journal-title":"Strahlenther Onkol"},{"issue":"3","key":"coi230018r15","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ijrobp.2011.08.017","article-title":"Adaptive radiotherapy for head-and-neck cancer: initial clinical outcomes from a prospective trial.","volume":"83","author":"Schwartz","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"coi230018r16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.radonc.2010.10.009","article-title":"The role of replanning in fractionated intensity modulated radiotherapy for nasopharyngeal carcinoma.","volume":"98","author":"Zhao","year":"2011","journal-title":"Radiother Oncol"},{"issue":"3","key":"coi230018r17","doi-asserted-by":"publisher","first-page":"985","DOI":"10.7314\/APJCP.2016.17.3.985","article-title":"Impact of adaptive radiotherapy on locally advanced head and neck cancer\u2014a dosimetric and volumetric study.","volume":"17","author":"Dewan","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"coi230018r18","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.radonc.2014.02.017","article-title":"Comparative dosimetry of three-phase adaptive and non-adaptive dose-painting IMRT for head-and-neck cancer.","volume":"111","author":"Olteanu","year":"2014","journal-title":"Radiother Oncol"},{"issue":"1","key":"coi230018r19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.radonc.2012.10.010","article-title":"Adaptive radiotherapy for head and neck cancer\u2013dosimetric results from a prospective clinical trial.","volume":"106","author":"Schwartz","year":"2013","journal-title":"Radiother Oncol"},{"issue":"1062","key":"coi230018r20","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20160085","article-title":"Clinical outcomes of adaptive radiotherapy in head and neck cancers.","volume":"89","author":"Kataria","year":"2016","journal-title":"Br J Radiol"},{"key":"coi230018r21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1748-717X-9-19","article-title":"Impact of body-mass factors on setup displacement in patients with head and neck cancer treated with radiotherapy using daily on-line image guidance.","volume":"9","author":"Lai","year":"2014","journal-title":"Radiat Oncol"},{"issue":"1","key":"coi230018r22","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/j.ijrobp.2012.09.033","article-title":"Replanning during intensity modulated radiation therapy improved quality of life in patients with nasopharyngeal carcinoma.","volume":"85","author":"Yang","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"coi230018r23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.radonc.2022.01.020","article-title":"Xerostomia quality of life and resource requirements following parotid sparing adaptive radiotherapy in head and neck cancers: results of a prospective cohort study (study ID CTRI\/2017\/11\/010683).","volume":"168","author":"Chatterjee","year":"2022","journal-title":"Radiother Oncol"},{"issue":"20","key":"coi230018r24","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"coi230018r25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1748-717X-1-7","article-title":"IMRT using simultaneously integrated boost (SIB) in head and neck cancer patients.","volume":"1","author":"Studer","year":"2006","journal-title":"Radiat Oncol"},{"issue":"1","key":"coi230018r26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","article-title":"An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.","volume":"21","author":"Adelstein","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi230018r27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1470-2045(11)70346-1","article-title":"Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.","volume":"13","author":"Bourhis","year":"2012","journal-title":"Lancet Oncol"},{"key":"coi230018r28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.radonc.2020.05.021","article-title":"Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial.","volume":"150","author":"Tao","year":"2020","journal-title":"Radiother Oncol"},{"issue":"1","key":"coi230018r29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1470-2045(09)70231-1","article-title":"Evidence-based organ-sparing radiotherapy in head and neck cancer.","volume":"11","author":"Dirix","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"coi230018r30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1034\/j.1601-0825.2002.02851.x","article-title":"Saliva and gastrointestinal functions of taste, mastication, swallowing and digestion.","volume":"8","author":"Pedersen","year":"2002","journal-title":"Oral Dis"},{"key":"coi230018r31","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3389\/fonc.2019.01090","article-title":"A review on the assessment of radiation induced salivary gland damage after radiotherapy.","volume":"9","author":"Wu","year":"2019","journal-title":"Front Oncol"},{"issue":"3","key":"coi230018r32","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0360-3016(01)01512-7","article-title":"Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer.","volume":"50","author":"Eisbruch","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"coi230018r33","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/(ISSN)1097-0347","article-title":"Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module.","volume":"29","author":"Rosenthal","year":"2007","journal-title":"Head Neck"},{"issue":"1","key":"coi230018r34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.radonc.2016.05.028","article-title":"Optimal adaptive IMRT strategy to spare the parotid glands in oropharyngeal cancer.","volume":"120","author":"Zhang","year":"2016","journal-title":"Radiother Oncol"},{"issue":"4","key":"coi230018r35","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"coi230018r36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1200\/JCO.20.02072","article-title":"ARTSCAN III: a randomized phase III study comparing chemoradiotherapy with cisplatin versus cetuximab in patients with locoregionally advanced head and neck squamous cell cancer.","volume":"39","author":"Gebre-Medhin","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi230018r37","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s13566-017-0336-1","article-title":"Image-guided adaptive radiotherapy improves acute toxicity during intensity-modulated radiation therapy for head and neck cancer.","volume":"7","author":"Chen","year":"2018","journal-title":"J Radiat Oncol"},{"issue":"11","key":"coi230018r38","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/hed.v36.11","article-title":"Clinical outcomes among patients with head and neck cancer treated by intensity-modulated radiotherapy with and without adaptive replanning.","volume":"36","author":"Chen","year":"2014","journal-title":"Head Neck"},{"key":"coi230018r39","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.105783","article-title":"The impact of head and neck radiotherapy on salivary flow and quality of life: results of the ORARAD study.","volume":"127","author":"Lin","year":"2022","journal-title":"Oral Oncol"},{"issue":"8","key":"coi230018r40","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.oraloncology.2011.05.012","article-title":"The impact of late treatment-toxicity on generic health-related quality of life in head and neck cancer patients after radiotherapy.","volume":"47","author":"Ramaekers","year":"2011","journal-title":"Oral Oncol"},{"issue":"3","key":"coi230018r41","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.radonc.2015.05.018","article-title":"Identifying patients who may benefit from adaptive radiotherapy: does the literature on anatomic and dosimetric changes in head and neck organs at risk during radiotherapy provide information to help?","volume":"115","author":"Brouwer","year":"2015","journal-title":"Radiother Oncol"},{"key":"coi230018r42","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13014-016-0650-6","article-title":"A nomogram to predict parotid gland overdose in head and neck IMRT.","volume":"11","author":"Castelli","year":"2016","journal-title":"Radiat Oncol"},{"key":"coi230018r43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.759724","article-title":"Patient-reported outcomes-guided adaptive radiation therapy for head and neck cancer.","volume":"11","author":"Weppler","year":"2021","journal-title":"Front Oncol"},{"key":"coi230018r44","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1471-2407-13-84","article-title":"Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer.","volume":"13","author":"Heukelom","year":"2013","journal-title":"BMC Cancer"},{"key":"coi230018r45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.616156","article-title":"MR-guided radiotherapy for head and neck cancer: current developments, perspectives, and challenges.","volume":"11","author":"Boeke","year":"2021","journal-title":"Front Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2805682\/jamaoncology_castelli_2023_oi_230018_1691789052.54476.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T15:25:05Z","timestamp":1692285905000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2805682"}},"subtitle":["A Phase 3 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2023.1352","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}